Its overexpression upon enzalutamide treatment of PCa cells confers resistance and inhibition of apoptosis. The process occurs through the RPS6KA–YB–1 signaling pathway and involves clusterin mediated activation of Akt and MAPK. The gene discussed is YBX1; the disease is posterior cortical atrophy.